BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 31668820)

  • 1. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
    Jiang Y; Ni W; Wu J
    BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
    Van Minh H; My NTT; Jit M
    BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    Mahumud RA; Alam K; Dunn J; Gow J
    PLoS One; 2019; 14(10):e0223658. PubMed ID: 31596899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran.
    Yaghoubi M; Nojomi M; Vaezi A; Erfani V; Mahmoudi S; Ezoji K; Zahraei SM; Chaudhri I; Moradi-Lakeh M
    Value Health Reg Issues; 2018 May; 15():112-119. PubMed ID: 29698864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.
    Kiendrébéogo JA; Sidibe ARO; Compaoré GB; Nacanabo R; Sory O; Ouédraogo I; Nawaz S; Schuind AE; Clark A
    BMC Health Serv Res; 2023 Dec; 23(1):1338. PubMed ID: 38041075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ; Tay SK; Teoh YL; Tok MY
    BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
    Mwenda V; Jalang'o R; Miano C; Bor JP; Nyangasi M; Mecca L; Were V; Kariithi E; Pecenka C; Schuind A; Abbas K; Clark A
    Vaccine; 2023 Jun; 41(29):4228-4238. PubMed ID: 37296015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
    Kiatpongsan S; Kim JJ
    PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
    Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
    BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model.
    Zhou L; Gu B; Wang J; Liu G; Zhang X
    BMC Public Health; 2022 Apr; 22(1):777. PubMed ID: 35436877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.